Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 1,694 trials

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Dapagliflozin for Patients Undergoing Heart Bypass Surgery

We are studying whether dapagliflozin can help prevent new heart rhythm problems and kidney issues in patients awaiting coronary artery bypass surgery. This research aims to improve recovery and overall outcomes after surgery.

Atrial Fibrillation and Acute Kidney Injury after CABG3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyInternal MedicineNephrology

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Bacterial Brain Abscess: Oral vs. IV Antibiotics

We are studying whether oral antibiotics are as effective as IV antibiotics for treating bacterial brain abscesses. This trial will help us understand the best treatment options and their impact on recovery and quality of life.

Brain Abscess>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNeurology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Psilocybin for Cancer-Related Depression

We are studying whether a single dose of psilocybin can help improve mood in adults aged 20-80 with major depression after a cancer diagnosis. Participants will compare its effects to a lower dose to assess changes in depressive symptoms.

Malignant TumorsMajor Depressive Disorder6-12 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteOncologyPsychiatry

Refractory Heart Failure: Dapagliflozin Study

We are investigating how Dapagliflozin may help patients with refractory heart failure eliminate sodium and manage fluid levels during peritoneal dialysis. This study aims to improve treatment options for these patients.

Refractory Heart Failure≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

Chronic Migraine in Adolescents: Rimegepant Study

We are investigating whether rimegepant can help prevent migraines in adolescents aged 12 to under 18 with chronic migraine. The study will also assess its safety and how it affects the use of other migraine treatments.

Chronic Migraine1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics